Your browser doesn't support javascript.
loading
Mazabraud's Syndrome: A Case Report and Up-To-Date Literature Review.
Vescini, Fabio; Falchetti, Alberto; Tonelli, Veronica; Carpentieri, Maria; Cipri, Claudia; Cosso, Roberta; Kara, Elda; Triggiani, Vincenzo; Grimaldi, Franco.
Afiliação
  • Vescini F; Endocrinology and Metabolism Unit, University-Hospital S. Maria della Misericordia of Udine, 33100 Udine, Italy.
  • Falchetti A; Villalba Clinic, Villa Maria Group, 40120 Bologna, Italy.
  • Tonelli V; EndOsmet, Villa Donatello Private Hospital, 50100 Florence, Italy.
  • Carpentieri M; Endocrinology and Metabolism Unit, University-Hospital S. Maria della Misericordia of Udine, 33100 Udine, Italy.
  • Cipri C; Endocrinology and Metabolism Unit, University-Hospital S. Maria della Misericordia of Udine, 33100 Udine, Italy.
  • Cosso R; Endocrinology and Metabolism Unit, University-Hospital S. Maria della Misericordia of Udine, 33100 Udine, Italy.
  • Kara E; EndOsmet, Villa Donatello Private Hospital, 50100 Florence, Italy.
  • Triggiani V; Endocrinology and Metabolism Unit, University-Hospital S. Maria della Misericordia of Udine, 33100 Udine, Italy.
  • Grimaldi F; Interdisciplinary Department of Medicine-Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, University of Bari "Aldo Moro", School of Medicine, 70100 Bari, Italy.
Article em En | MEDLINE | ID: mdl-30585553
ABSTRACT

OBJECTIVE:

Mazabraud's syndrome is a rare form of bone fibrous dysplasia associated with intramuscular myxomas. Fibrous dysplasia, is generally localized to pelvis and femur and it results in a fragile bone with deformities, pain, pathological fractures and functional impairment. Intramuscular myxomas, are rare benign mesenchymal neoplasms that exceptionally may evolve to malignant forms.

METHODS:

This case report describes a 66-year-old woman with Mazabraud's Syndrome (MS), characterized both by monostotic right femur fibrous dysplasia and by a solitary intramuscular myxoma at the right quadriceps muscle, that underwent a long-term treatment (4 years) with intravenous zoledronic acid.

RESULTS:

Zoledronic acid therapy rapidly lowered bone pain together with a reduction of intramuscular myxoma volume, but did not affect the extension of fibrous dysplasia. No adverse effects have been observed during treatment.

CONCLUSION:

Highly active bisphosphonates are commonly used for the treatment of bone metabolic disorders and they are generally well tolerated. Zoledronic acid may represent a promising alternative to surgical intervention in MS, although its use in rare form of bone fibrous dysplasias is still controversial.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Musculares / Displasia Fibrosa Óssea / Mixoma Tipo de estudo: Diagnostic_studies Limite: Aged / Female / Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Musculares / Displasia Fibrosa Óssea / Mixoma Tipo de estudo: Diagnostic_studies Limite: Aged / Female / Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article